Rather, we demonstrate how inherent differences in PRPS1 and PRPS2 activity can be leveraged to elicit opposing effects on redox homeostasis to selectively target Myc-overexpressing lymphomas with compounds acting on key oxidizing or reducing machineries. This evidence concerns the gene MYC and lymphoma.